Liquidia Corp

LQDA

Market cap $5.64B

Does Liquidia Corporation (LQDA) have what it takes to be a top stock pick for momentum investors? Let's find out.

MORRISVILLE, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an update on the company's business in a fireside chat at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026, at 12:45 p.m.

Middle East tensions are stoking volatility; a low-beta screen spotlights Liquidia, Exxon Mobil, Valero Energy and Diamondback Energy.

Liquidia Corporation (LQDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Liquidia Corporation (LQDA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

LQDA, NEXA and NUE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 13th, 2026.

HCSG, NUE, NEXA, LQDA and NKSH have been added to the Zacks Rank #1 (Strong Buy) List on May 13th, 2026.

Liquidia Corp (NASDAQ:LQDA) on Monday reported better-than-expected first-quarter financial results.

Liquidia delivered strong Q1 results, with Yutrepia net sales up 44% sequentially and a third consecutive profitable quarter. LQDA now commands a 23% share of the inhaled prostacyclin segment, but further market share gains are likely capped by entrenched competitors and limited product differentiation. At a near $5 billion market cap and 9x run-rate revenue, the current valuation assumes sustained momentum and peak Yutrepia sales north of $1.2 billion, which appears optimistic.

Liquidia stock broke out to a record high Monday after the company smashed first-quarter sales expectations.